Association between health-related quality of life, symptoms of anxiety, and depression at discharge and 3-year HF medication non-adherencea
| Continuous PRO data . | Dichotomized PRO data . | ||||
|---|---|---|---|---|---|
| . | Crude OR . | Adjusted OR . | . | Crude OR . | Adjusted OR . |
| (95% CI) . | (95% CI)b . | (95% CI) . | (95% CI)b . | ||
| ACEI/ARB/ARNI, n = 1188 | ACEI/ARB/ARNI, n = 1188 | ||||
| EQ-5D-5L | 3.18 (1.42–7.09) | 2.78 (1.19–6.49) | EQ-5D-5L | 1.33 (0.97–1.82) | 1.30 (0.94–1.79) |
| HeartQoL global | 1.17 (0.99–1.37) | 1.12 (0.94–1.33) | HeartQoL global | 1.01 (0.75–1.36) | 0.96 (0.71–1.31) |
| HADS-A | 1.03 (0.99–1.06) | 1.03 (0.99–1.06) | HADS-A | 1.11 (0.85–1.45) | 1.12 (0.84–1.48) |
| HADS-D | 1.08 (1.04–1.12) | 1.07 (1.03–1.11) | HADS-D | 1.64 (1.20–2.23) | 1.55 (1.12–2.14) |
| β-blockers, n = 1248 | β-blockers, n = 1248 | ||||
| EQ-5D-5L | 3.51 (1.62–7.60) | 2.35 (1.04–5.29) | EQ-5D-5L | 1.55 (1.15–2.09) | 1.38 (1.01–1.89) |
| HeartQoL global | 1.27 (1.09–1.49) | 1.17 (0.99–1.37) | HeartQoL global | 1.54 (1.14–2.07) | 1.37 (1.01–1.87) |
| HADS-A | 1.02 (0.99–1.05) | 1.01 (0.98–1.04) | HADS-A | 1.11 (0.86–1.43) | 1.03 (0.79–1.35) |
| HADS-D | 1.07 (1.04–1.11) | 1.06 (1.02–1.10) | HADS-D | 1.70 (1.26–2.29) | 1.53 (1.13–2.08) |
| MRAs, n = 686 | MRAs, n = 686 | ||||
| EQ-5D-5L | 0.94 (0.34–2.55) | 0.87 (0.30–2.53) | EQ-5D-5L | 0.72 (0.49–1.05) | 0.71 (0.47–1.06) |
| HeartQoL global | 1.07 (0.87–1.33) | 1.06 (0.85–1.33) | HeartQoL global | 0.87 (0.60–1.27) | 0.85 (0.57–1.26) |
| HADS-A | 0.97 (0.94–1.01) | 0.98 (0.94–1.02) | HADS-A | 0.77 (0.55–1.08) | 0.77 (0.54–1.10) |
| HADS-D | 1.01 (0.96–1.05) | 1.01 (0.96–1.05) | HADS-D | 0.94 (0.64–1.38) | 0.97 (0.64–1.46) |
| Continuous PRO data . | Dichotomized PRO data . | ||||
|---|---|---|---|---|---|
| . | Crude OR . | Adjusted OR . | . | Crude OR . | Adjusted OR . |
| (95% CI) . | (95% CI)b . | (95% CI) . | (95% CI)b . | ||
| ACEI/ARB/ARNI, n = 1188 | ACEI/ARB/ARNI, n = 1188 | ||||
| EQ-5D-5L | 3.18 (1.42–7.09) | 2.78 (1.19–6.49) | EQ-5D-5L | 1.33 (0.97–1.82) | 1.30 (0.94–1.79) |
| HeartQoL global | 1.17 (0.99–1.37) | 1.12 (0.94–1.33) | HeartQoL global | 1.01 (0.75–1.36) | 0.96 (0.71–1.31) |
| HADS-A | 1.03 (0.99–1.06) | 1.03 (0.99–1.06) | HADS-A | 1.11 (0.85–1.45) | 1.12 (0.84–1.48) |
| HADS-D | 1.08 (1.04–1.12) | 1.07 (1.03–1.11) | HADS-D | 1.64 (1.20–2.23) | 1.55 (1.12–2.14) |
| β-blockers, n = 1248 | β-blockers, n = 1248 | ||||
| EQ-5D-5L | 3.51 (1.62–7.60) | 2.35 (1.04–5.29) | EQ-5D-5L | 1.55 (1.15–2.09) | 1.38 (1.01–1.89) |
| HeartQoL global | 1.27 (1.09–1.49) | 1.17 (0.99–1.37) | HeartQoL global | 1.54 (1.14–2.07) | 1.37 (1.01–1.87) |
| HADS-A | 1.02 (0.99–1.05) | 1.01 (0.98–1.04) | HADS-A | 1.11 (0.86–1.43) | 1.03 (0.79–1.35) |
| HADS-D | 1.07 (1.04–1.11) | 1.06 (1.02–1.10) | HADS-D | 1.70 (1.26–2.29) | 1.53 (1.13–2.08) |
| MRAs, n = 686 | MRAs, n = 686 | ||||
| EQ-5D-5L | 0.94 (0.34–2.55) | 0.87 (0.30–2.53) | EQ-5D-5L | 0.72 (0.49–1.05) | 0.71 (0.47–1.06) |
| HeartQoL global | 1.07 (0.87–1.33) | 1.06 (0.85–1.33) | HeartQoL global | 0.87 (0.60–1.27) | 0.85 (0.57–1.26) |
| HADS-A | 0.97 (0.94–1.01) | 0.98 (0.94–1.02) | HADS-A | 0.77 (0.55–1.08) | 0.77 (0.54–1.10) |
| HADS-D | 1.01 (0.96–1.05) | 1.01 (0.96–1.05) | HADS-D | 0.94 (0.64–1.38) | 0.97 (0.64–1.46) |
ACEI, angiotensin–converting–enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; CI, confidence interval; EQ-5D-5L, the EuroQoL five-dimensional, five-level questionnaire; HADS-A, Hospital Anxiety and Depression Scale, anxiety; HADS-D, Hospital Anxiety and Depression Scale; HeartQoL global, the HeartQoL global score; MRAs, mineralocorticoid receptor antagonists; OR, odds ratio.
Multivariable logistic regression.
OR were adjusted for the following: age, sex, length of hospital stay, Charlson comorbidity index score, left ventricular ejection fraction, social support, device-related procedure, incident HF, and systolic blood pressure (mmHg).
Association between health-related quality of life, symptoms of anxiety, and depression at discharge and 3-year HF medication non-adherencea
| Continuous PRO data . | Dichotomized PRO data . | ||||
|---|---|---|---|---|---|
| . | Crude OR . | Adjusted OR . | . | Crude OR . | Adjusted OR . |
| (95% CI) . | (95% CI)b . | (95% CI) . | (95% CI)b . | ||
| ACEI/ARB/ARNI, n = 1188 | ACEI/ARB/ARNI, n = 1188 | ||||
| EQ-5D-5L | 3.18 (1.42–7.09) | 2.78 (1.19–6.49) | EQ-5D-5L | 1.33 (0.97–1.82) | 1.30 (0.94–1.79) |
| HeartQoL global | 1.17 (0.99–1.37) | 1.12 (0.94–1.33) | HeartQoL global | 1.01 (0.75–1.36) | 0.96 (0.71–1.31) |
| HADS-A | 1.03 (0.99–1.06) | 1.03 (0.99–1.06) | HADS-A | 1.11 (0.85–1.45) | 1.12 (0.84–1.48) |
| HADS-D | 1.08 (1.04–1.12) | 1.07 (1.03–1.11) | HADS-D | 1.64 (1.20–2.23) | 1.55 (1.12–2.14) |
| β-blockers, n = 1248 | β-blockers, n = 1248 | ||||
| EQ-5D-5L | 3.51 (1.62–7.60) | 2.35 (1.04–5.29) | EQ-5D-5L | 1.55 (1.15–2.09) | 1.38 (1.01–1.89) |
| HeartQoL global | 1.27 (1.09–1.49) | 1.17 (0.99–1.37) | HeartQoL global | 1.54 (1.14–2.07) | 1.37 (1.01–1.87) |
| HADS-A | 1.02 (0.99–1.05) | 1.01 (0.98–1.04) | HADS-A | 1.11 (0.86–1.43) | 1.03 (0.79–1.35) |
| HADS-D | 1.07 (1.04–1.11) | 1.06 (1.02–1.10) | HADS-D | 1.70 (1.26–2.29) | 1.53 (1.13–2.08) |
| MRAs, n = 686 | MRAs, n = 686 | ||||
| EQ-5D-5L | 0.94 (0.34–2.55) | 0.87 (0.30–2.53) | EQ-5D-5L | 0.72 (0.49–1.05) | 0.71 (0.47–1.06) |
| HeartQoL global | 1.07 (0.87–1.33) | 1.06 (0.85–1.33) | HeartQoL global | 0.87 (0.60–1.27) | 0.85 (0.57–1.26) |
| HADS-A | 0.97 (0.94–1.01) | 0.98 (0.94–1.02) | HADS-A | 0.77 (0.55–1.08) | 0.77 (0.54–1.10) |
| HADS-D | 1.01 (0.96–1.05) | 1.01 (0.96–1.05) | HADS-D | 0.94 (0.64–1.38) | 0.97 (0.64–1.46) |
| Continuous PRO data . | Dichotomized PRO data . | ||||
|---|---|---|---|---|---|
| . | Crude OR . | Adjusted OR . | . | Crude OR . | Adjusted OR . |
| (95% CI) . | (95% CI)b . | (95% CI) . | (95% CI)b . | ||
| ACEI/ARB/ARNI, n = 1188 | ACEI/ARB/ARNI, n = 1188 | ||||
| EQ-5D-5L | 3.18 (1.42–7.09) | 2.78 (1.19–6.49) | EQ-5D-5L | 1.33 (0.97–1.82) | 1.30 (0.94–1.79) |
| HeartQoL global | 1.17 (0.99–1.37) | 1.12 (0.94–1.33) | HeartQoL global | 1.01 (0.75–1.36) | 0.96 (0.71–1.31) |
| HADS-A | 1.03 (0.99–1.06) | 1.03 (0.99–1.06) | HADS-A | 1.11 (0.85–1.45) | 1.12 (0.84–1.48) |
| HADS-D | 1.08 (1.04–1.12) | 1.07 (1.03–1.11) | HADS-D | 1.64 (1.20–2.23) | 1.55 (1.12–2.14) |
| β-blockers, n = 1248 | β-blockers, n = 1248 | ||||
| EQ-5D-5L | 3.51 (1.62–7.60) | 2.35 (1.04–5.29) | EQ-5D-5L | 1.55 (1.15–2.09) | 1.38 (1.01–1.89) |
| HeartQoL global | 1.27 (1.09–1.49) | 1.17 (0.99–1.37) | HeartQoL global | 1.54 (1.14–2.07) | 1.37 (1.01–1.87) |
| HADS-A | 1.02 (0.99–1.05) | 1.01 (0.98–1.04) | HADS-A | 1.11 (0.86–1.43) | 1.03 (0.79–1.35) |
| HADS-D | 1.07 (1.04–1.11) | 1.06 (1.02–1.10) | HADS-D | 1.70 (1.26–2.29) | 1.53 (1.13–2.08) |
| MRAs, n = 686 | MRAs, n = 686 | ||||
| EQ-5D-5L | 0.94 (0.34–2.55) | 0.87 (0.30–2.53) | EQ-5D-5L | 0.72 (0.49–1.05) | 0.71 (0.47–1.06) |
| HeartQoL global | 1.07 (0.87–1.33) | 1.06 (0.85–1.33) | HeartQoL global | 0.87 (0.60–1.27) | 0.85 (0.57–1.26) |
| HADS-A | 0.97 (0.94–1.01) | 0.98 (0.94–1.02) | HADS-A | 0.77 (0.55–1.08) | 0.77 (0.54–1.10) |
| HADS-D | 1.01 (0.96–1.05) | 1.01 (0.96–1.05) | HADS-D | 0.94 (0.64–1.38) | 0.97 (0.64–1.46) |
ACEI, angiotensin–converting–enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; CI, confidence interval; EQ-5D-5L, the EuroQoL five-dimensional, five-level questionnaire; HADS-A, Hospital Anxiety and Depression Scale, anxiety; HADS-D, Hospital Anxiety and Depression Scale; HeartQoL global, the HeartQoL global score; MRAs, mineralocorticoid receptor antagonists; OR, odds ratio.
Multivariable logistic regression.
OR were adjusted for the following: age, sex, length of hospital stay, Charlson comorbidity index score, left ventricular ejection fraction, social support, device-related procedure, incident HF, and systolic blood pressure (mmHg).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
